Key Points
- CFO Kevin Dennis Green sold 55,225 shares on March 5 at an average of $2.06 (≈$113,763) and another 27,796 shares on March 6 at $2.01 (≈$55,870), trimming his stake by 4.41% to 1,195,891 shares.
- Cerus posted a revenue beat—$64.58M vs. $59.31M consensus—but reported ($0.01) EPS with a negative net margin (7.58%) and negative ROE (26.09%); the stock has a $340.1M market cap and a 12‑month range of $1.12–$2.96.
- Institutional investors own 78.37% of the shares and analyst coverage is mixed (one Buy, one Sell), giving an average rating of Hold.
Cerus Corporation (NASDAQ:CERS - Get Free Report) CFO Kevin Dennis Green sold 55,225 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $2.06, for a total value of $113,763.50. Following the completion of the sale, the chief financial officer directly owned 1,195,891 shares of the company's stock, valued at $2,463,535.46. This trade represents a 4.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Kevin Dennis Green also recently made the following trade(s):
- On Friday, March 6th, Kevin Dennis Green sold 27,796 shares of Cerus stock. The stock was sold at an average price of $2.01, for a total value of $55,869.96.
Cerus Stock Performance
NASDAQ CERS opened at $1.77 on Wednesday. The company has a market cap of $340.14 million, a P/E ratio of -22.13 and a beta of 1.51. The company has a fifty day simple moving average of $2.30 and a 200 day simple moving average of $1.86. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. Cerus Corporation has a 12-month low of $1.12 and a 12-month high of $2.96.
Cerus (NASDAQ:CERS - Get Free Report) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The firm had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. Sell-side analysts predict that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cerus
A number of hedge funds have recently bought and sold shares of CERS. Assenagon Asset Management S.A. boosted its holdings in Cerus by 29.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,583,702 shares of the biotechnology company's stock worth $2,518,000 after purchasing an additional 358,548 shares during the last quarter. Acadian Asset Management LLC increased its stake in Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company's stock valued at $3,710,000 after buying an additional 733,683 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Cerus by 49.2% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 296,099 shares of the biotechnology company's stock valued at $418,000 after buying an additional 97,592 shares during the last quarter. Savant Capital LLC lifted its position in shares of Cerus by 339.6% during the 2nd quarter. Savant Capital LLC now owns 94,812 shares of the biotechnology company's stock worth $134,000 after buying an additional 73,244 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in shares of Cerus by 30.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 367,389 shares of the biotechnology company's stock worth $518,000 after buying an additional 85,835 shares in the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the stock. TD Cowen reaffirmed a "buy" rating on shares of Cerus in a research report on Monday, January 12th. Wall Street Zen lowered Cerus from a "buy" rating to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold".
Check Out Our Latest Stock Analysis on Cerus
Cerus Company Profile
(
Get Free Report)
Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.
The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
